Cartiva has enrolled the first patient in a study of its FDA-cleared ProxiFuse Hammertoe Compression System.
Here are six things to know:
1. This multicenter, prospective, observational, post-market study aims to further demonstrate the safety and effectiveness of the ProxiFuse system.
2. The system is designed for the fixation of osteotomies and reconstruction of the lesser toes following correction procedures for hammertoe, claw toe and mallet toe.
3. The first study patient was successfully treated by John Maskill, MD, at the Metro Health/OAM Surgery Center in Grand Rapids, Mich.
4. Dr. Maskill is an orthopedic surgeon practicing at Orthopaedic Associates of Michigan in Grand Rapids.
5. The study will enroll a minimum of 70 patients at six sites throughout the United States.
6. Outcomes will be collected and measured using the National Institutes of Health Patient Reported Outcome Measurement Information System.